Literature DB >> 17620384

Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model.

Chun-Hong Tan1, Jian Li, Roger L Nation.   

Abstract

Three clinically relevant intermittent regimens, and a continuous infusion, of colistin were simulated in an in vitro pharmacokinetic/pharmacodynamic model against two colistin-heteroresistant strains of Acinetobacter baumannii. Extensive initial killing was followed by regrowth as early as 6 h later; bacterial density in the 24- to 72-h period was within 1 log(10) CFU/ml of growth control. Population analysis profiles revealed extensive emergence of resistant subpopulations regardless of the colistin regimen.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17620384      PMCID: PMC2043182          DOI: 10.1128/AAC.01571-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration.

Authors:  J Li; C R Rayner; R L Nation; R Deans; R Boots; N Widdecombe; A Douglas; J Lipman
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

2.  Cure of multidrug-resistant Acinetobacter baumannii fixation device-related orthopedic infections in two patients with intravenous colistin.

Authors:  Sofia K Kasiakou; Kostas Fragoulis; George Tzagarakis; Panagiotis Mistidis; Anastasios Kapaskelis; Matthew E Falagas
Journal:  Microb Drug Resist       Date:  2005       Impact factor: 3.431

3.  Using intrathecal colistin for multidrug resistant shunt infection.

Authors:  H Sueke; H Marsh; A Dhital
Journal:  Br J Neurosurg       Date:  2005-02       Impact factor: 1.596

4.  Old polymyxins are back: is resistance close?

Authors:  Jian Li; Roger L Nation
Journal:  Clin Infect Dis       Date:  2006-09-01       Impact factor: 9.079

5.  Multidrug-resistant Acinetobacter: a threat to the antibiotic era.

Authors:  A Y Peleg; D L Paterson
Journal:  Intern Med J       Date:  2006-08       Impact factor: 2.048

Review 6.  Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.

Authors:  George H Talbot; John Bradley; John E Edwards; David Gilbert; Michael Scheld; John G Bartlett
Journal:  Clin Infect Dis       Date:  2005-01-25       Impact factor: 9.079

7.  Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa.

Authors:  Phillip J Bergen; Jian Li; Craig R Rayner; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

8.  Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study.

Authors:  Rosa Reina; Elisa Estenssoro; Gabriela Sáenz; Héctor S Canales; Romina Gonzalvo; Gabriela Vidal; Gustavo Martins; Andrea Das Neves; Oscar Santander; Carlos Ramos
Journal:  Intensive Care Med       Date:  2005-06-28       Impact factor: 17.440

9.  Overview of nosocomial infections caused by gram-negative bacilli.

Authors:  Robert Gaynes; Jonathan R Edwards
Journal:  Clin Infect Dis       Date:  2005-08-16       Impact factor: 9.079

10.  Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004).

Authors:  A C Gales; R N Jones; H S Sader
Journal:  Clin Microbiol Infect       Date:  2006-04       Impact factor: 8.067

View more
  44 in total

1.  fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.

Authors:  Rajesh V Dudhani; John D Turnidge; Roger L Nation; Jian Li
Journal:  J Antimicrob Chemother       Date:  2010-06-23       Impact factor: 5.790

Review 2.  Dosing of colistin-back to basic PK/PD.

Authors:  Phillip J Bergen; Jian Li; Roger L Nation
Journal:  Curr Opin Pharmacol       Date:  2011-08-09       Impact factor: 5.547

3.  Colistin heteroresistance in acinetobacter and its association with previous colistin therapy.

Authors:  Joshua S Hawley; Clinton K Murray; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

4.  Stable polymyxin B susceptibility to Pseudomonas aeruginosa and Acinetobacter spp. despite persistent recovery of these organisms from respiratory secretions of patients with ventilator-associated pneumonia treated with this drug.

Authors:  Alexandre P Zavascki; Jian Li; Roger L Nation; Silvana V Superti; Afonso L Barth; Larissa Lutz; Fabiano Ramos; Márcio M Boniatti; Luciano Z Goldani
Journal:  J Clin Microbiol       Date:  2009-07-08       Impact factor: 5.948

5.  Interaction of colistin and colistin methanesulfonate with liposomes: colloidal aspects and implications for formulation.

Authors:  Stephanie J Wallace; Jian Li; Roger L Nation; Richard J Prankerd; Ben J Boyd
Journal:  J Pharm Sci       Date:  2012-05-23       Impact factor: 3.534

Review 6.  Colistin and polymyxin B: peas in a pod, or chalk and cheese?

Authors:  Roger L Nation; Tony Velkov; Jian Li
Journal:  Clin Infect Dis       Date:  2014-04-03       Impact factor: 9.079

7.  The transcriptomic response of Acinetobacter baumannii to colistin and doripenem alone and in combination in an in vitro pharmacokinetics/pharmacodynamics model.

Authors:  Rebekah Henry; Bethany Crane; David Powell; Deanna Deveson Lucas; Zhifeng Li; Jesús Aranda; Paul Harrison; Roger L Nation; Ben Adler; Marina Harper; John D Boyce; Jian Li
Journal:  J Antimicrob Chemother       Date:  2015-01-14       Impact factor: 5.790

Review 8.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

9.  Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Hee Ji Lee; Phillip J Bergen; Jurgen B Bulitta; Brian Tsuji; Alan Forrest; Roger L Nation; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191

10.  Extensively drug-resistant Acinetobacter baumannii.

Authors:  Yohei Doi; Shahid Husain; Brian A Potoski; Kenneth R McCurry; David L Paterson
Journal:  Emerg Infect Dis       Date:  2009-06       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.